IPA trade ideas
$IPA entry PT 10.60-11.20 PT 20 and higherImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
IPA publishes its scientific paper "Cornering an Ever-Evolving Coronavirus: TATX-03, a Fully Human, Synergistic, Multi-Antibody Cocktail Targeting the SARS-CoV-2 Spike Protein with in vivo Efficacy" on bioRxiv
VICTORIA, British Columbia, July 22, 2021--(BUSINESS WIRE)--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced new results from its TATX-03 PolyTope™ Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta (B.1.617.2) variant.
The Company anticipated viral evolution leading to novel SARS-CoV-2 variants of concern throughout the design of their PolyTope SARS-CoV-2 therapeutic cocktail, aiming to minimize the risk of mutagenic escape (a reduction or elimination in the efficacy of a therapy or vaccine by virus mutation). As such, the Company continuously validates, and has demonstrated to date, maintained neutralization potency of IPA’s multi-antibody cocktail towards SARS-CoV-2 variants of concern. IPA previously announced that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPA’s TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant (B.1.617.2). Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta (B.1.617.1) variant with the majority showing maintained binding. These results are consistent with previously announced binding data towards other SARS-CoV-2 mutants, including variants of concern Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants. These binding data, combined with the maintained neutralization potency of IPA’s TATX-03 to variants of concern, supports the Company’s expectation that rationally designed multi-membered antibody cocktails are more sustainable, e.g. will be functionally less prone to escape-by-one mutations.
"The data from IPA’s screenings on the variants of concern speak to the importance of targeting diversified epitopes on the spike trimer for treatment sustainability and resilience of our PolyTope cocktail," stated Dr. Ilse Roodink, IPA’s Chief Scientific Officer and Global Program Director for COVID Research. "Our TATX-03 cocktail is rationally designed for broad epitope coverage relying on multiple antibodies, which have shown in pre-clinical studies to work synergistically together, to reduce the risk of mutagenic escape, and have the potential to reduce the risk of new variants. We believe this strategy of multi-antibody cocktails is more crucial now with the surge of new variants of concern and breakthrough cases."
IPA’s paper "Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy" (doi.org) describes the Company’s approach to designing TATX-03, including the extensive characterization studies and in vivo efficacy trials which supported the rational design of the antibody cocktail, and which demonstrates sustained pre-clinical efficacy to emerging variants of concern.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com
IPA Fibbing Right Now Needs 786 Hold?IPA is the latest retail banger this week after NURO and CEMI took center stage during the first half. I took out the fibs back to the previous lows and plotted against the ATH. Interesting levels formed which showed pivot support/resistance at the 786 fib line and the 618 maintaining a secondary level of importance. After failing to break and hold above it, longs may be looking to see this 786 fib level to hold as a new support. This move was on COVID news with "potential" in the headline. So take that FWIW. Also have the upcoming corporate call next week on the 28th.
" Over the last few days alone, we’ve seen seriously bullish action in the stock market. Today former penny stock ImmunoPrecise (NASDAQ:IPA) was the latest to grab attention from retail traders. On Monday (7/19), IPA stock was traded around $5 with a volume of fewer than 60,000 shares. Fast-forward to today (7/22), and IPA stock reached highs of $16.47 before the afternoon session got into full swing, with more than 60 million shares traded...This wasn’t an outlier either. Other stocks this week like Chembio Diagnostics, Inc. (NASDAQ:CEMI) and NeuroMetrix Inc. (NASDAQ:NURO) made parabolic moves as well. CEMI stock jumped from lows of $2.20 to highs of $6.95, while NURO stock jumped from around $3 on Monday to over $40 today. "
Quote Source: 7 Penny Stocks To Buy According To Analysts With Targets Up To 316%
$IPA ImmunoPreciseGood news and even better volume today. We should see this build a base around $10 - $12. Earnings on the 29th should be interesting.
VWAP rejected and momentum slowed down.
Long $IPA. There is no way big pharma doesn't like this play.
$IPA is gonna fall todayPupm&Dump trading strategy idea.
$IPA is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $7,88;
stop-loss — $9,01;
take-profit — $5,62.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
